EGFR and breast neoplasm: Recently, disulfide bond-disrupting agents (DDAs), including RBF3 [30] and tcyDTDO [31], have been shown to kill breast tumors with acquired resistance to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors.